BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021;74:1200-1211. [PMID: 33484770 DOI: 10.1016/j.jhep.2021.01.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Riveiro-Barciela M, Palom A, Buti M. Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer? Aliment Pharmacol Ther 2022;56:912-3. [PMID: 35934854 DOI: 10.1111/apt.17115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Burm R, Maravelia P, Ahlen G, Ciesek S, Caro Perez N, Pasetto A, Urban S, Van Houtte F, Verhoye L, Wedemeyer H, Johansson M, Frelin L, Sällberg M, Meuleman P. Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections. Gut 2022:gutjnl-2022-327216. [PMID: 35977815 DOI: 10.1136/gutjnl-2022-327216] [Reference Citation Analysis]
3 Degasperi E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Scholtes C, Facchetti F, Loglio A, Monico S, Fraquelli M, Costantino A, Ceriotti F, Zoulim F, Lampertico P. Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension. J Hepatol 2022:S0168-8278(22)02980-4. [PMID: 35973578 DOI: 10.1016/j.jhep.2022.07.016] [Reference Citation Analysis]
4 Caviglia GP, Ciancio A, Rizzetto M. A Review of HDV Infection. Viruses 2022;14:1749. [DOI: 10.3390/v14081749] [Reference Citation Analysis]
5 Palom A, Rando-segura A, Vico J, Pacín B, Vargas E, Barreira-díaz A, Rodríguez-frías F, Riveiro-barciela M, Esteban R, Buti M. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100547] [Reference Citation Analysis]
6 Soriano V, de Mendoza C, Treviño A, Ramos-Rincón JM, Moreno-Torres V, Corral O, Barreiro P. Treatment of Hepatitis Delta and HIV Infection. Liver Int 2022. [PMID: 35748639 DOI: 10.1111/liv.15345] [Reference Citation Analysis]
7 Lazarus JV, Al-Rifai A, Sanai FM, Alghamdi AS, Sharara AI, Saad MF, van Selm L, Alqahtani SA. Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: A scoping review. Liver Int 2022. [PMID: 35689428 DOI: 10.1111/liv.15338] [Reference Citation Analysis]
8 Dietz CA, Cornberg M. Lonafarnib-A new member of the Delta Force? Hepatology 2022;75:1370-2. [PMID: 35229339 DOI: 10.1002/hep.32435] [Reference Citation Analysis]
9 Huang Y, Qin A, Tsai C, Chen P. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. Viruses 2022;14:1128. [DOI: 10.3390/v14061128] [Reference Citation Analysis]
10 Zhang Z, Ni Y, Lempp FA, Walter L, Mutz P, Bartenschlager R, Urban S. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.05.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Martini S, Tandoi F, Romagnoli R, Rizzetto M. Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected Recipients. Transplantation 2022;Publish Ahead of Print. [DOI: 10.1097/tp.0000000000004138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Usai C, Gill US, Riddell AC, Asselah T, Kennedy PT. Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus. Aliment Pharmacol Ther 2022;55:978-93. [PMID: 35292991 DOI: 10.1111/apt.16807] [Reference Citation Analysis]
13 Olivero A, Rosso C, Ciancio A, Abate ML, Nicolosi A, Troshina G, Armandi A, Ribaldone DG, Saracco GM, Bugianesi E, Rizzetto M, Caviglia GP. Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. Biomedicines 2022;10:792. [DOI: 10.3390/biomedicines10040792] [Reference Citation Analysis]
14 Brancaccio G, Shanyinde M, Puoti M, Gaeta GB, Monforte AD, Vergori A, Rusconi S, Mazzarelli A, Castagna A, Antinori A, Cozzi-lepri A. Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. Pathogens and Global Health. [DOI: 10.1080/20477724.2022.2047551] [Reference Citation Analysis]
15 Osiowy C, Swidinsky K, Haylock-jacobs S, Sadler MD, Fung S, Wong D, Minuk GY, Doucette KE, Wong P, Tam E, Cooper C, Ramji A, Ma M, Nudo C, Tsoi K, Coffin CS. Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100461] [Reference Citation Analysis]
16 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 49.0] [Reference Citation Analysis]
17 Kushner T, Da BL, Chan A, Dieterich D, Sigel K, Saberi B. Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era. Transplant Direct 2022;8:e1253. [PMID: 34957333 DOI: 10.1097/TXD.0000000000001253] [Reference Citation Analysis]
18 Jachs M, Binter T, Schmidbauer C, Hartl L, Strasser M, Laferl H, Hametner-Schreil S, Lindorfer A, Dax K, Stauber RE, Kessler HH, Bernhofer S, Maieron A, Loacker L, Bota S, Santonja I, Munda P, Mandorfer M, Peck-Radosavljevic M, Holzmann H, Gschwantler M, Zoller H, Ferenci P, Reiberger T. Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterol J 2021;9:1119-27. [PMID: 34873866 DOI: 10.1002/ueg2.12163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Lok AS, Negro F, Asselah T, Farci P, Rizzetto M. Endpoints and New Options for Treatment of Chronic Hepatitis D. Hepatology 2021;74:3479-85. [PMID: 34331781 DOI: 10.1002/hep.32082] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
20 Sonkar A, Bishwal SC, Sharma RK, Barde PV. Prevalence of Hepatitis D virus antibodies in Hepatitis B patients treated at tertiary care unit at Jabalpur Central India. Indian J Med Microbiol 2021:S0255-0857(21)04707-1. [PMID: 34801290 DOI: 10.1016/j.ijmmb.2021.11.003] [Reference Citation Analysis]
21 Bogomolov PO, Ivashkin VT, Bueverov AO, Maev IV, Sagalova OI, Sleptsova SS, Yushuk ND, Gusev DA, Zhdanov KV, Chulanov VP. Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis. Terapevticheskii arkhiv 2021;93:1290-9. [DOI: 10.26442/00403660.2021.11.201163] [Reference Citation Analysis]
22 Ramos-Rincon JM, Pinargote H, Ramos-Belinchón C, de Mendoza C, Aguilera A, Soriano V. Hepatitis delta in patients hospitalized in Spain (1997-2018). AIDS 2021;35:2311-8. [PMID: 34261094 DOI: 10.1097/QAD.0000000000003024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Soriano V, Alvarez C, Edagwa B, de Mendoza C, Montoya N, Treviño A, Gendelman H. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. Int J Infect Dis 2021;114:45-50. [PMID: 34728344 DOI: 10.1016/j.ijid.2021.10.052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol 2021:S0168-8278(21)02119-X. [PMID: 34699951 DOI: 10.1016/j.jhep.2021.10.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 15.0] [Reference Citation Analysis]
25 Prestileo T, Di Marco V, Dino O, Sanfilippo A, Tutone M, Milesi M, Di Marco L, Picchio CA, Craxì A, Lazarus JV; Immigrant Take Care Advocacy (ITaCA) team. Effectiveness of a screening program for HBV, HCV, and HIV infections in African migrants to Sicily. Dig Liver Dis 2021:S1590-8658(21)00765-9. [PMID: 34649829 DOI: 10.1016/j.dld.2021.08.024] [Reference Citation Analysis]
26 Sandmann L, Wedemeyer H. New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. Clin Liver Dis 2021;25:831-9. [PMID: 34593156 DOI: 10.1016/j.cld.2021.06.011] [Reference Citation Analysis]
27 Tout I, Loureiro D, Asselah T. The Changing Demographics of Hepatitis B Virus Infection. Clin Liver Dis 2021;25:673-87. [PMID: 34593147 DOI: 10.1016/j.cld.2021.06.001] [Reference Citation Analysis]
28 Muhammad H, Zaffar D, Tehreem A, Ting P, Simsek C, Gokcan H, Gurakar A, Idilman R. HBV/HDV management after liver transplantation: Review. Journal of Liver Transplantation 2021;4:100046. [DOI: 10.1016/j.liver.2021.100046] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lee AU, Lee C. Hepatitis D Review: Challenges for the Resource-Poor Setting. Viruses 2021;13:1912. [PMID: 34696341 DOI: 10.3390/v13101912] [Reference Citation Analysis]
30 Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut 2021;70:1782-94. [PMID: 34103404 DOI: 10.1136/gutjnl-2020-323888] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 32.0] [Reference Citation Analysis]
31 Salimi Alizei E, Hofmann M, Thimme R, Neumann-Haefelin C. Mutational escape from cellular immunity in viral hepatitis: variations on a theme. Curr Opin Virol 2021;50:110-8. [PMID: 34454351 DOI: 10.1016/j.coviro.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Soriano V, Mendoza C, Barreiro P, Treviño A, Corral O. Envisioning a hepatitis delta cure with new antivirals. Future Microbiol 2021;16:927-30. [PMID: 34406066 DOI: 10.2217/fmb-2021-0177] [Reference Citation Analysis]
33 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
34 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
35 Dandri M, Bertoletti A, Lütgehetmann M. Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition. Semin Immunopathol 2021. [PMID: 34019142 DOI: 10.1007/s00281-021-00864-x] [Reference Citation Analysis]
36 Farci P, Niro GA, Zamboni F, Diaz G. Hepatitis D Virus and Hepatocellular Carcinoma. Viruses 2021;13:830. [PMID: 34064419 DOI: 10.3390/v13050830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
37 Tseligka ED, Clément S, Negro F. HDV Pathogenesis: Unravelling Ariadne's Thread. Viruses 2021;13:778. [PMID: 33924806 DOI: 10.3390/v13050778] [Reference Citation Analysis]
38 Giersch K, Dandri M. In Vivo Models of HDV Infection: Is Humanizing NTCP Enough? Viruses 2021;13:588. [PMID: 33807170 DOI: 10.3390/v13040588] [Reference Citation Analysis]
39 Rizzetto M, Stroffolini T. Forty-Five Years after the Discovery of the Hepatitis D Virus: Where Do We Stand? Viruses 2021;13:555. [PMID: 33810224 DOI: 10.3390/v13040555] [Reference Citation Analysis]